Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

John M. Burke, Enrico De Nigris, Yunfei Wang et al. Nov 03, 2025 pp. 2111-2111 10.1182/blood-2025-2111

Abstract INTRODUCTION cBTKis have become a standard 1L therapy for CLL/SLL. While second-generation (2G) cBTKis, acalabrutinib (Acala) and za...

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Kenneth JC Lim, Ricardo Parrondo, Saurabh Chhabra et al. Nov 03, 2025 pp. 5953-5953 10.1182/blood-2025-5953

Abstract Introduction Cila-cel is associated with a 10-15% risk of delayed neurotoxicity (DNT) with rates of cranial nerve palsies (IEC-NP)...

Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition

Nour Nassour, JeeEun Choi, Qi Yan et al. Nov 03, 2025 pp. 4083-4083 10.1182/blood-2025-4083

Abstract Introduction The gut microbiome has been studied in preclinical inflammatory disease models. Dysbiosis, where normal gut bacteria ar...

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Elisabetta Todisco, Caterina Alati, Ernesta Audisio et al. Nov 03, 2025 pp. 3384-3384 10.1182/blood-2025-3384

Abstract INTRODUCTION In Italy, the combination of Venetoclax+Azacitidine (Ven/Aza) is approved, as the standard of care...

Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML

Emily Batterham, Jules Higue, Ashish Bajel et al. Nov 03, 2025 pp. 3465-3465 10.1182/blood-2025-3465

Abstract Background: Prolonged neutropenia and infectious complications represent an important concern during the first induction cycle of az...

Generative AI–Powered clinical decision support in germline predisposition to myeloid neoplasms

Carmelo Gurnari, Carlos Pérez Míguez, Davide Crucitti et al. Nov 03, 2025 pp. 2556-2556 10.1182/blood-2025-2556

Abstract Introduction The exploration of germline predispositions to myeloid neoplasms (MNs) has gained significant traction, particularly w...

Multiple HLA-loss clones are required for hematologic regeneration in immune aplastic anemia

Miku Kobayashi, Yoshitaka Zaimoku Nov 03, 2025 pp. 1434-1434 10.1182/blood-2025-1434

Abstract Background In patients with immune aplastic anemia, hematopoietic stem cells deficient in specific HLA class I alleles can evade cy...

Menstruation-induced vaso-occlusive crisis in women with sickle cell disease

Sherraine Della-Moretta, Rina Welkie, Ryan Hicks et al. Nov 03, 2025 pp. 4445-4445 10.1182/blood-2025-4445

Abstract Introduction: Sickle cell disease (SCD) affects approximately 100,000 people in the United States. Pain is a well-known complicatio...

Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes

Matteo Zampini, Elena Riva, Nicolas Sompairac et al. Nov 03, 2025 pp. 3830-3830 10.1182/blood-2025-3830

Abstract Background. Myelodysplastic Syndromes (MDS) present an increased risk of progression to Acute Myeloid Leukemia (AML). The complex in...

Targeting BRD9 in KMT2A-rearranged Acute Myeloid Leukemia to circumvent MEN1 inhibitor resistance

Jenny Hsiao-Wen Huang, Eve Ioannou, Tommaso De Marchi et al. Nov 03, 2025 pp. 1463-1463 10.1182/blood-2025-1463

Abstract Introduction: Acute myeloid leukemia (AML) with rearrangement of the KMT2A gene (KMT2Ar) is a blood malignancy with adverse clinica...

Vincristine-induced neuropathy: Long term follow-up of lymphoma survivors treated with CHOP or dose-adjusted EPOCH chemotherapy

Gretchen McNally, Laura Flora, Surith Krishna et al. Nov 03, 2025 pp. 8076-8076 10.1182/blood-2025-8076

Abstract Introduction: The incidence of Vincristine-induced neuropathy (VIN) occurs in up to 70% of non Hodgkin Lymphoma...

The complex dance of immunity: A review of secondary HLH in HIV (2000-2025)

Musa Kiyani, Samantha Vogt Nov 03, 2025 pp. 6546-6546 10.1182/blood-2025-6546

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome marked by severe i...

Characteristics, treatment outcomes, and prognostic analysis of 118 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia

Yangzhi Zhao, Wei Guo, Jia Li et al. Nov 03, 2025 pp. 3608-3608 10.1182/blood-2025-3608

Abstract Background : Lymphoplasmacytic Lymphoma/Waldenström macroglobulinemia (LPL/WM) is a rare B-cell lymphoma consist of lymphocytes,lymp...

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Marie Sebert, Valeria Santini, Uwe Platzbecker et al. Nov 03, 2025 pp. 8254-8254 10.1182/blood-2025-8254

Abstract Background and Significance: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal myeloid disorders that prima...

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan et al. Nov 03, 2025 pp. 5379-5379 10.1182/blood-2025-5379

Abstract Background: Marginal Zone Lymphoma (MZL) is a group of B-cell malignancies. Orelabrutinib (ORE), the first approved BTKi in China f...

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Lu Zhang, Rui Chen, Yujun Dong et al. Nov 03, 2025 pp. 4787-4787 10.1182/blood-2025-4787

Abstract Interleukin-6 (IL-6) targeted therapy has been recommended as the most important treatment option for idiopathic Multicentric Castl...

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Peng Liu, Koji Kato, Sai Li et al. Nov 03, 2025 pp. 8082-8082 10.1182/blood-2025-8082

Abstract Introduction: The phase III POLARIX study (NCT03274492) demonstrated the superiority of Polatuzumab vedotin (Pola) combined with ri...

Genetic deletion of vasoactive intestinal peptide (VIP) and PI3K signaling pathways impair CAR T cell function

Yujie Chen, Ronald Roberts, Dejah Blake et al. Nov 03, 2025 pp. 7633-7633 10.1182/blood-2025-7633

Abstract Introduction: The clinical efficacy of chimeric antigen receptor (CAR) T cell therapy remains limited in solid tumors, with immunos...

Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis

Vaishali Gautam, Benjamin Mescher, Rishab Prakash et al. Nov 03, 2025 pp. 604-604 10.1182/blood-2025-604

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) in adults with acute myeloid leukemia (AML) represents a devastating hyperin...

External validation of TTP-14: A novel machine learning model that improves rapid diagnosis of immune TTP

Mouhamed Yazan Abou-Ismail, Meera Sridharan, Chong Zhang et al. Nov 03, 2025 pp. 850-850 10.1182/blood-2025-850

Abstract Background Due to the high mortality of immune thrombotic thrombocytopenic purpura (iTTP), rapid clinical evaluation and early inte...

Differentiation of human induced pluripotent stem cells expressing chimeric antigen receptors into distinct immune cells as an off-the-shelf strategy for tumor treatments

Paula Ribeiro, Erika Salles, Luana Catharino et al. Nov 03, 2025 pp. 4136-4136 10.1182/blood-2025-4136

Abstract Immunotherapy based on T cells expressing Chimeric Antigen Receptor (CAR- T) has been shown to be a promising strategy for treating...

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Aarif Ahsan, Christine Mantis, Adam Luo et al. Nov 03, 2025 pp. 2204-2204 10.1182/blood-2025-2204

Abstract Background Etentamig is a second-generation B-cell maturation antigen (BCMA) x CD3 bispecific antibody that has shown promising eff...

Single vs double cord blood transplantation: Improved engraftment with comparable efficacy

Alessandra Azure, Mizuki Watanabe, Laura Roberts et al. Nov 03, 2025 pp. 7736-7736 10.1182/blood-2025-7736

Abstract Background: For patients with hematologic malignancies, cord blood (CB) is a widely accepted source of hematopoietic stem cells. Du...

Heme oxygenase-1 facilitates immune evasion in diffuse large B-cell lymphoma by reprogramming tumor-associated macrophage polarization

Wenbin Lei, JiShi Wang Nov 03, 2025 pp. 5085-5085 10.1182/blood-2025-5085

Abstract Objective: Diffuse Large B-cell Lymphoma (DLBCL) is a hematologic malignancy characterized by the clonal expansion of myeloid proge...

Is PPM1D a potential driver of myeloid malignancy transformation in neuroendocrine tumor (NET) patients: An underrecognized malignant CHIPeRpetRaTor?

Kirti Arora, Spencer Rosario, Kelly Jans et al. Nov 03, 2025 pp. 6711-6711 10.1182/blood-2025-6711

Abstract Background: Building on our prior work showing high baseline CHIP prevalence and cytopenias in NET patients (pt...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page